Integrating molecular and immune biomarkers for precision therapy in hepatitis B: Associated hepatocellular carcinoma.

In this editorial, we comment on the article by Wang et al, which investigates molecular and immune biomarkers predictive of response to sintilimab plus lenvatinib in hepatitis B virus-associated hepatocellular carcinoma (HCC). Yet, despite remarkable progress with immune-checkpoint and anti-angiogenic combinations, the biological heterogeneity of HCC continues to limit durable responses and individualized care. By integrating high-resolution transcriptomic, exomic, and immune-cell-profiling data, Wang et al identified a coherent triad - elevated LINC01554 expression, enrichment of CD4+ central-memory T cells, and solitary-tumour morphology - that independently predicted prolonged progression-free survival. This constellation links tumour-intrinsic transcriptional restraint, adaptive immune competence, and anatomical containment, illustrating how multi-omic profiling can clarify determinants of therapeutic benefit. These insights signify a shift from empiricism to biologically guided therapy, providing a scaffold for biologic stratification, longitudinal response monitoring, and rational sequencing of immunotherapeutic and anti-angiogenic agents. Collectively, they redefine HCC as a dynamic biological ecosystem rather than a uniform malignancy and highlight the imperative to embed multi-omic biomarker platforms within future clinical-trial design - marking a decisive step toward precision hepatology in inflammation-driven cancers.